News
S*BIO Oral JAK-2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and other Hematological Disorders
S*BIO Expands Pipeline with the Development of a Unique Flt3 – CDK Inhibitor as a Targeted Therapy for Acute Leukemias
S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
S*BIO Becomes Singapore's First Biotech Company to Initiate Clinical Trial of Novel Anti-Cancer Drug
S*BIO and National University Hospital-National University of Singapore Tissue Repository to Partner on Tumor Biomarker Research
S*BIO and A*STAR To Develop New Compounds To Treat Cancer
S*BIO Announces Research Collaboration with Karolinska Institutet
S*BIO Announces Incorporation of SBIO INC. and the Opening of US Operations
| |
S*BIO Vision
S*BIO targets defined molecular pathways to inhibit the development of select tumour types, positioning us as a leader in oncology drug discovery research.
S*BIO translates a profound understanding of cancer biology into best-in-class clinical compounds, establishing us as a preferred partner and collaborator in the development of innovative cancer treatments.
S*BIO transforms the lives of people with cancer by creating breakthrough therapies with improved clinical outcomes, demonstrating our determination to be a driving force in the fight against cancer.
|
